Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Turcot syndrome × Immunotherapy × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 37 Lung Neoplasms 14 Melanoma 13 Neoplasm Metastasis 12 Esophageal Neoplasms 10 Carcinoma, Hepatocellular 10 Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Esophageal Squamous Cell Carcinoma 6 Rectal Neoplasms 5 Head and Neck Neoplasms 5 Colorectal Neoplasms 5 Stomach Neoplasms 4 Brain Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Recurrence 3 Neoplasms 3 Multiple Myeloma 3 Cholangiocarcinoma 3 Carcinoma, Renal Cell 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Neuroblastoma 2 Neoplasm, Residual 2 Nasopharyngeal Carcinoma 2 Locally Advanced Non-small Cell Lung Cancer 2

Interventions

pembrolizumab 4 Nivolumab 3 sintilimab 2 Neoadjuvant Therapy 2 toripalimab 1 tislelizumab 1 spartalizumab 1 relatlimab 1 regorafenib 1 fludarabine phosphate 1 fludarabine 1 durvalumab 1 denileukin diftitox 1 danvatirsen 1 avelumab 1 atezolizumab 1 Taxes 1 Surgical Procedures, Operative 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Megestrol Acetate 1 Medroxyprogesterone Acetate 1 Ipilimumab 1 Induction Chemotherapy 1 Immunotherapy 1 Immunoglobulin G 1 Immune Checkpoint Inhibitors 1 IMM-101 1 E7777 fusion protein 1 Disulfides 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07259473 2026-01-07

Pre-CATALIS

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting

Turcot syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡